Earlier quoted context omitted.
Seems pretty simple, really. 1000 patients come in with symptoms that look like cancer at year 0. 100 actually get diagnosed with cancer at some point between year 0 and year 5. Presumably, the remaining 900 didn't have cancer at year 0.
"Seems". You can't know what fraction of your remaining 900 had cancer but weren't diagnosed with it for any of a wide variety of reasons, from death through misadventure, through false negative, to simple loss to followup. Clinical studies are designed to exclude such confounding outcomes. It's very difficult to see how any study of this data could be designed to do likewise.
Especially for the NHS dataset, since you will either see the patient in there or in a death index (unlike, say, US where they may have just gone to another hospital).
Also, the scope here is more like a longitudinal vaccine study than a clinical trial. 50M people will provide a lot of robustness that you wouldn't see in a 1000 patient trial.